|
|
||||||||
From the Laboratory of Ocular Pharmacology and Physiology, University Eye Clinic Basel, Basel, Switzerland.
| Abstract |
|---|
|
|
|---|
METHODS. In a myograph system (isometric force measurement), precontracted vessels (
0.1 µM U46619; thromboxane A2 analogue or
10 nM endothelin-1) were exposed, in a cumulative manner, to increasing concentrations of adrenomedullin (1 nM to 1 µM) in the presence or absence of different drugs. Some experiments were conducted in vessels with nonfunctional (intentionally mechanically damaged) endothelium.
RESULTS. Adrenomedullin evoked marked relaxation [maximum relaxation (Relmax): 85.5 ± 3.0%; negative log M concentration inducing 50% of Relmax (pD2): 7.4 ± 0.1] in comparison to time-controls (Relmax: 19.2 ±4.8%; P < 0.001). Relaxation was inhibited by 3 µM CGRP[8-37] (CGRP1 receptor antagonist; Relmax: 27.2% ± 5.3%; P < 0.001) but not by 3 µM adrenomedullin[22-52] (presumed adrenomedullin receptor antagonist; P = 0.75). Adrenomedullin-induced relaxation was less pronounced in nonfunctional endothelium vessels (Relmax: 67.6% ± 3.1%; pD2: 6.9 ± 0.1; P < 0.01). In vessels with functional endothelium, relaxation was not significantly influenced by 0.1 mM NG-nitro-L-arginine methyl ester (L-NAME; a nitric oxide synthesis inhibitor), 10 µM indomethacin (a cyclooxygenase inhibitor), or 10 µM 17-octadecynoic acid (a cytochrome P450 inhibitor). In contrast, relaxation was significantly inhibited by either 10 mM tetraethylammonium (nonselective potassium channel inhibitor; P < 0.01) or 50 nM apamin (small conductance potassium channel inhibitor), together with 50 nM charybdotoxin (large and intermediate potassium channel inhibitor; P < 0.01). In the presence of these potassium channel inhibitors, the amount of relaxation was not significantly different (P > 0.50) from that observed in vessels with nonfunctional endothelium.
CONCLUSIONS. In isolated porcine ciliary arteries, adrenomedullin induces relaxation that involves CGRP1 receptors and is in part endothelium dependent. Endothelium-dependent relaxation was blocked by some potassium channel inhibitors, suggesting the possible release of an endothelium-derived hyperpolarizing factor (EDHF).
Adrenomedullin, which can be produced and secreted by various types of cells, such as cardiomyocytes, fibroblasts, macrophages, neurons, glial cells, retinal pigment epithelial cells, vascular smooth muscle cells, and vascular endothelial cells6 has vasodilatory properties. In some vessels, this relaxation is in part mediated by the release of endothelium-derived relaxation factors.7 8 9 Indeed, the vascular endothelium has the ability to release vasorelaxing substances, such as nitric oxide (NO), prostacyclin, and the putative endothelium-derived hyperpolarizing factor (EDHF). It has been reported that, in kidney arteries of the dog,10 or the hindquarters vascular bed of the rat,11 part of the adrenomedullin-induced relaxation is mediated by NO. In the human coronary arterioles it has further been shown that adrenomedullin elicits vasodilatation in part through the production of NO and in part through the activation of potassium channels.12 In contrast, in some vessels, such as canine central retinal artery, an endothelium-dependent adrenomedullin-induced relaxation was not demonstrated.13 It has been reported that part of the biological activities of adrenomedullin are mediated by CGRP receptors, but the question of whether a specific adrenomedullin receptor exists is still debated.14 15
The major purpose of the present study was to investigate the role that is played by endothelium-derived relaxation factors in the relaxation induced by adrenomedullin in isolated porcine ciliary arteries.
| Materials and Methods |
|---|
|
|
|---|
950 mg).17 Vessels were then exposed several times to 100 mM KCl until they showed reproducible contractions (i.e., <10% variation between two successive KCl-induced contractions). The functional integrity of the endothelium was assessed by relaxing the vessels with bradykinin. The endothelial function was considered to be intact if bradykinin (100 nM1 µM) evoked 80% relaxation of a vessel precontracted with the thromboxane A2 analogue U46619 (0.1 µM).18 In some vessels the integrity of the endothelium was compromised by rubbing the luminal surface of the vessels with a human scalp hair. In these vessels with a nonfunctional endothelium, bradykinin evoked no relaxation. All vessels were then washed out with modified Krebs-Ringer solution before any of the experimental protocols described below were conducted.
Experimental Protocol
Arteries precontracted with U46619 (
0.1 µM) were exposed to increasing concentrations of adrenomedullin (1 nM to 1 µM). Concentrationresponse curves were constructed in the absence or in the presence of: (1) CGRP[8-37] (1 and 3 µM), a CGRP1 receptor antagonist; (2) adrenomedullin[22-52] (AM[22-52], 1 and 3 µM), an adrenomedullin receptor antagonist; (3) NG-nitro-L-arginine methyl ester (L-NAME; 0.1 mM), an inhibitor of NO formation; (4) tetraethylammonium (TEA, 10 mM), a nonselective potassium channel inhibitor; (5) a combination of Ca2+-dependent potassium channel inhibitors, apamin (50 nM), which inhibits small-conductance potassium channels, and charybdotoxin (ChTX, 50 nM), which inhibits large- and intermediate-conductance potassium channels; and (6) 17-octadecynoic acid (17-ODYA, 10 µM), a cytochrome P450 inhibitor. Furthermore, concentrationresponse curves to sodium nitroprusside (SNP, 1 nM to 0.3 mM) were constructed in the absence or presence of CGRP[8-37] (0.1 µM). In one additional set of experiments, vessels were precontracted with endothelin-1 (
10 nM) and concentrationresponse curves to adrenomedullin were constructed in the absence or presence of indomethacin (10 µM), an inhibitor of cyclooxygenase, because it has been reported that the latter can significantly attenuate the contractions induced by U46619.19 The preincubation time for all these drugs was 30 minutes.
Drugs
Bradykinin, L-NAME, indomethacin, U46619, SNP, 17-ODYA, TEA, apamin, and ChTX were purchased from Sigma-Aldrich (Buchs, Switzerland). Adrenomedullin (human), adrenomedullin[22-52], and CGRP[8-37] were bought from Bachem AG (Bubendorf, Switzerland) and endothelin-1 from Novabiochem (Laufelfingen, Switzerland). All drugs were dissolved in distilled water except indomethacin, 17-ODYA, and endothelin-1, which were dissolved in 10 µM Na2CO3, ethanol, and Krebs solution containing 0.05% bovine serum albumin, respectively. Concentrations are expressed as final molar concentrations in the organ chambers.
Statistical Analysis
Results are given as the mean ± SEM, with n equaling the number of eyes (one eye per animal) studied. Relaxation is expressed as a percentage of the maximum contraction evoked by U46619 (
0.1 µM) or endothelin-1 (
10 nM). The EC50, or the concentration causing 50% of the maximum relaxation (Relmax), is expressed as a negative log M concentration (pD2). Statistical comparisons were conducted with a one-way ANOVA multiple comparison followed by the Bonferroni test, with a two-tailed P < 0.05 considered to be statistically significant.
| Results |
|---|
|
|
|---|
0.1 µM), adrenomedullin (1 nM to 1 µM) evoked potent concentration-dependent relaxation (Relmax: 85.5% ± 3.0%, pD2 = 7.4 ± 0.1). The adrenomedullin-induced relaxation was inhibited by the CGRP1 receptor antagonist CGRP[8-37] in a dose-dependent manner (1 µM, Relmax: 64.7% ± 4.8%; 3 µM Relmax: 27.2% ± 5.3%, P < 0.001 vs. control, Fig. 1A ). The relaxation evoked by adrenomedullin in the presence of 3 µM CGRP[8-37] was not significantly different (P = 0.62) from the spontaneous loss of tone observed in time-control experiments (Relmax: 19.2% ± 4.8%, Fig. 1A ). In contrast, the relaxation induced by adrenomedullin was not affected by AM[22-52], a drug that has been reported to have some adrenomedullin receptor antagonist properties14 15 (1 µM, Relmax= 112.0% ± 4.6%; 3 µM Relmax = 115.7% ± 9.4%, P = 0.75 vs. control; Fig. 1B ). To exclude an unspecific inhibitory effect of CGRP[8-37] on the relaxing properties of the vessels, the effect of CGRP[8-37] was also tested on the relaxation induced by SNP. The relaxation evoked by SNP (1 nM to 0.3 mM; n = 10; Relmax = 89.3% ± 4.7%) was not significantly affected by CGRP[8-37] (10 µM; n = 7; Relmax = 76.6% ± 8.8%, P = 0.22 vs. control, Fig. 2 ). These results tend to indicate that adrenomedullin relaxes porcine ciliary arteries essentially through the activation of CGRP1 receptors or receptors that have a common structural homology with CGRP1 receptors.
|
|
0.1 µM) precontracted vessels with a nonfunctional endothelium (intentionally and mechanically damaged), relaxation evoked by adrenomedullin (1 nM to 1 µM) was significantly blunted (Relmax = 67.6% ± 3.1%, pD2 = 6.9 ± 0.1, P < 0.01; Fig. 3 ) demonstrating that, in porcine ciliary arteries, relaxation induced by adrenomedullin was in part endothelium dependent.
|
0.1 µM) precontracted vessels relaxation evoked by adrenomedullin was not significantly affected by the presence of the inhibitor of NO formation L-NAME (0.1 mM) at a concentration known to inhibit endothelium-dependent NO production18 (Fig. 4A) . Relaxation evoked by adrenomedullin was also unaffected by the presence of indomethacin in endothelin-1 (
10 nM) precontracted vessels at a concentration of indomethacin reported to inhibit cyclooxygenase20 (Fig. 4B) . These results demonstrate that adrenomedullin does not relax porcine ciliary arteries through the release of nitric oxide or a prostaglandin produced after cyclooxygenase activation.
|
0.1 µM) precontracted vessels, in the absence or in the presence of different potassium channel inhibitors. First, the effect of TEA (10 mM), a nonselective potassium channel inhibitor was investigated. Then, experiments were conducted with a combination of Ca2+-dependent potassium channel inhibitors, apamin (50 nM), a small-conductance potassium channel inhibitor and ChTX (50 nM), a large- and intermediate-conductance potassium channel inhibitor. In vessels with a functional endothelium, relaxation evoked by adrenomedullin was significantly blunted by TEA (Relmax = 62.1% ± 5.0%, P < 0.01; Fig. 5A ), as well as by apamin together with ChTX (Relmax = 53.8% ± 6.8%, P < 0.01; Fig. 5B ). Such an inhibitory effect of TEA, or apamin+ChTX on adrenomedullin-induced relaxation was not observed in vessels with a nonfunctional endothelium. In vessels with a functional endothelium, the relaxation evoked by adrenomedullin in the presence of the potassium channel inhibitors was not significantly different (P > 0.50) from the relaxation observed in vessels with a nonfunctional endothelium (Fig. 5) . These results suggest that the endothelium-dependent relaxation induced by adrenomedullin involves the activation of potassium channels, suggesting the possible presence of an EDHF.
|
|
| Discussion |
|---|
|
|
|---|
The amino acid sequence of adrenomedullin has some homology with calcitonin gene-related peptide (CGRP), and adrenomedullin is therefore considered to be a member of the CGRP superfamily. In the present study the relaxing effect of adrenomedullin was blocked by the CGRP1 receptor antagonist CGRP[8-37], indicating that the relaxing effect of adrenomedullin is mainly mediated by the activation of CGRP1 receptors in porcine ciliary arteries. This observation is in agreement with other reports made in the literature on the relaxing effect of adrenomedullin.14 22
It has been suggested that in some vascular beds, the effect of adrenomedullin could be mediated by a specific adrenomedullin receptor and the adrenomedullin fragment AM[22-52] has been used as specific adrenomedullin receptor antagonist by some investigators.15 For example, pretreatment with 100 nM AM[22-52] could attenuate the vasodilation induced by adrenomedullin in human coronary arterioles.15 In porcine ciliary arteries, we could not confirm this hypothesis, because the relaxation evoked by adrenomedullin was not significantly affected by the adrenomedullin receptor antagonist AM[22-52], even at a concentration as high as 3 µM. Our results are in agreement with other reports conducted in the canine mesenteric arteries and porcine coronary arteries, showing that adrenomedullin-induced relaxation was not affected by AM[22-52].23 24 It also should be mentioned that the AM[22-52] fragment is considered by some investigators not to be a very potent adrenomedullin inhibitor, and its specificity has also been questioned.15 24
Adrenomedullin has been shown to induce vasodilatation, both through endothelium-dependent8 9 and -independent mechanisms.13 25 In this regard, it is interesting to note that heterogeneity can exist between different species or between different vascular beds in the mechanisms involved in adrenomedullin-induced relaxation. For example it has been reported that in canine retinal arteries, adrenomedullin induces only endothelium-independent relaxation.13 In contrast, in porcine ciliary arteries we demonstrated that the relaxing effect of adrenomedullin is in part endothelium dependent.
Usually, three major factors are considered to be involved in endothelium-dependent relaxation: NO, prostacyclin, and EDHF.26 27 In the kidneys of the dog or in the hindquarters of the rat, NO has been shown to mediate endothelium-dependent relaxation induced by adrenomedullin.10 11 In rat pulmonary artery rings in hypoxic conditions, adrenomedullin-induced relaxation was abolished by 10 µM indomethacin, an inhibitor of cyclooxygenase.9 In the porcine ciliary artery, it appeared that adrenomedullin-induced endothelium-dependent relaxation did not involve NO, because the relaxing effect of this peptide was not significantly affected by L-NAME. Also, prostacyclin did not appear to mediate the relaxing effect of adrenomedullin in porcine ciliary arteries, because the adrenomedullin-induced relaxation was unaffected by indomethacin.
The endothelium-derived factor EDHF relaxes smooth muscle cells through the opening of potassium channels in these cells.27 The present study shows that in porcine ciliary arteries, the relaxation evoked by adrenomedullin was partially blunted by several inhibitors of potassium channels. The effect of these potassium channel inhibitors was observed only in vessels with a functional endothelium but not in vessels with a mechanically and intentionally damaged nonfunctional endothelium, suggesting the involvement of potassium channels in the endothelium-dependent relaxing effect of adrenomedullin. These observations indicate the possible presence of an EDHF in the endothelium-dependent relaxation evoked by adrenomedullin. These results are in agreement with other reports showing the activation of potassium channels in the adrenomedullin-induced relaxation in rat kidney28 and human coronary arterioles as well.12
The chemical nature and the physiological role of the EDHF are still unclear. It has been proposed that arachidonic acid metabolites produced by the cytochrome P450 monooxygenase pathway (epoxyeicosatrienoic acids) may act as an EDHF.29 30 Indeed, arachidonic acid metabolites have been shown to induce hyperpolarization in arterial smooth muscle cells. It has been reported, for example, that the EDHF-mediated component of an endothelium-dependent relaxation is blunted by inhibitors of cytochrome P450, such as SKF 525A and miconazole in bovine coronary artery30 and 17-ODYA in rabbit carotid artery.21 These findings could not be confirmed in other vessels,31 32 suggesting that different factors may represent EDHF. In our study conducted in isolated porcine ciliary arteries, adrenomedullin-induced relaxation was not significantly affected by the cytochrome P450 inhibitor 17-ODYA. Therefore, it is unlikely that a cytochrome P450derived metabolite of arachidonic acid is involved in the EDHF-induced activation of potassium channels evoked by adrenomedullin in porcine ciliary arteries.
In conclusion, adrenomedullin evoked in porcine ciliary arteries potent relaxation that was in part endothelium dependent and appeared to involve the activation of CGRP1 receptors. Furthermore, the endothelium-dependent component of this relaxation was blocked by some potassium channel inhibitors, suggesting the presence of an EDHF.
| Footnotes |
|---|
Submitted for publication December 20, 2002; revised April 8, 2003; accepted April 11, 2003.
Disclosure: E.S. Dettmann, None; I. Vysniauskiene, None; R. Wu, None; J. Flammer, None; I.O. Haefliger, None
The publication costs of this article were defrayed in part by page charge payment. This article must therefore be marked "advertisement" in accordance with 18 U.S.C.
1734 solely to indicate this fact.
Corresponding author: Ivan O. Haefliger, Laboratory of Ocular Pharmacology and Physiology, University Eye Clinic Basel, Mittlere Strasse 91, PO Box, CH-4012 Basel, Switzerland.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
I. Vysniauskiene, R. Allemann, J. Flammer, and I. O. Haefliger Vasoactive Responses of U46619, PGF2{alpha}, Latanoprost, and Travoprost in Isolated Porcine Ciliary Arteries Invest. Ophthalmol. Vis. Sci., January 1, 2006; 47(1): 295 - 298. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Cleary, C H Buckley, E Henry, P McLoughlin, C O'Brien, and P W F Hadoke Enhanced endothelium derived hyperpolarising factor activity in resistance arteries from normal pressure glaucoma patients: implications for vascular function in the eye Br. J. Ophthalmol., February 1, 2005; 89(2): 223 - 228. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |